Great question and great perspective in the response. It is my opinion that both RVX and Zenith are epigenetic R & D production factories with a very long lead on their understanding of BETi and pan BET inhibitors. There credibility is growing slowly as evidenced by independent scientists experimenting with apabetalone. They seem to engineer a compound with a specific target in mind and then test it in the test tube/agar plate, then animals and if it shows evidence of positive impact they move to the clinical level once the early stages of safety are demonstrated.

I think it has been extensively discussed but I sense the share price has been suppressed by a number of factors including;

1. The shell shock of June 2013 (ASSURE failure to regress PAV).
2. The structure of the tightly held shares (although from my perspective the quality of companies invested is an advantage... the only issue is willl they be fair to us retail holders?).
3. Lack of a NASDAQ listing and no desire to get one.
4. Uncertainty regarding the LOC on Aug 28th. No question that it will get done.
5. The structure of the new financing in terms of potential dilution.
6. Waiting until the FA is complete.
7. Lack of independent analysts coverage.
8. Don's reputation.
9. Etc.

FDA approval was not a boast but wonderful to have.

While many great things are happening scientifically I question why any investor would jump in now. There is absolutely no reason to rush other than an exceptionally low share price.

tada, I agree with your perspective on R & D. This what the company is. Look what they have achieved on very small budgets!

Cheers

Toinv